Table 4.
Cardiovascular outcomes before and after propensity score matching.
| Total Study Population | After PSM | |||||||
|---|---|---|---|---|---|---|---|---|
| Conservative (N = 392) |
Invasive (N = 798) |
HR * (95% CI) | p-Value | Conservative (N = 319) |
Invasive (N = 319) |
HR (95% CI) | p-Value | |
| MACE | 78 (20%) | 93 (12%) | 0.53 (0.37–0.77) | 0.001 | 57 (18%) | 38 (12%) | 0.50 (0.31–0.81) | 0.004 |
| NACE | 128 (33%) | 167 (21%) | 0.65 (0.49–0.86) | 0.003 | 91 (29%) | 70 (22%) | 0.69 (0.48–0.99) | 0.045 |
| All-cause death | 100 (26%) | 70 (9%) | 0.36 (0.25–0.52) | <0.001 | 70 (22%) | 37 (12%) | 0.46 (0.29–0.74) | 0.001 |
| CV death | 49 (13%) | 32 (4%) | 0.35 (0.21–0.60) | <0.001 | 36 (11%) | 19 (6%) | 0.47 (0.24–0.90) | 0.023 |
| Recurrent ACS | 32 (8%) | 49 (6%) | 0.47 (0.28–0.78) | 0.004 | 22 (7%) | 16 (5%) | 0.56 (0.27–1.17) | 0.123 |
| Stroke | 1 (0.3%) | 11 (1%) | 2.62 (0.31–22.3) | 0.378 | 1 (0.3%) | 0 | ||
| Major bleeding | 7 (2%) | 48 (6%) | 2.24 (0.96–5.22) | 0.062 | 4 (1%) | 24 (8%) | 4.37 (1.50–12.8) | 0.007 |
| Non-major and clinically relevant bleeding | 22 (6%) | 113 (14%) | 1.94 (1.16–3.23) | 0.012 | 17 (5%) | 53 (17%) | 2.52 (1.40–4.51) | 0.002 |
| Periprocedural bleeding | 0 | 27 (3%) | NA | NA | 0 | 13 (4%) | NA | NA |
* Hazard ratios in the total study population were adjusted for multiple baseline characteristics (Table S1). Data are n (%). ACS = acute coronary syndrome; CV = cardiovascular; MACE = Major Adverse Cardiac events; NACE = Net Adverse Clinical Events.